This article is more than 5 years old. Information may no longer be current.

Xalatan sales jump 14% in 2002

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PEAPACK, N.J. — Full-year sales of the glaucoma medication Xalatan increased 14% to $928 million. The increased sales helped propel marketer Pharmacia to post an 8% increase in sales for the year.

For the fourth quarter of 2002, worldwide sales of Xalatan (latanoprost) increased to $243 million from $226 million in the same quarter of 2001. A company press release said Xalatan is the No. 1 prescribed glaucoma medication in the United States, Europe and Japan.

In late December, the U.S. Food and Drug Administration approved Xalatan as first-line therapy for elevated eye pressure associated with open-angle glaucoma or ocular hypertension. The approval made Xalatan the first and only prostaglandin with first-line indication in all three major markets.

In addition, Pharmacia won lawsuits filed against Allergan over patent issues relating to Allergan’s bimatoprost and Pharmacia’s latanoprost products. Under terms of the agreement, Allergan will pay royalties to Pharmacia. Pharmacia has reported gain of 5 cents per share in connection with the suit.

In December, Pharmacia shareholders approved a proposal to be acquired by Pfizer. Pharmacia expects the acquisition to be complete some time during the first quarter of this year.